Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vor Biopharma Inc
(NQ:
VOR
)
1.800
+0.040 (+2.27%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vor Biopharma Inc
< Previous
1
2
Next >
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
May 02, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
April 01, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
March 20, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
March 04, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
January 17, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 21, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit
November 27, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
November 09, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
November 07, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 03, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
November 03, 2023
From
Vor Biopharma
Via
GlobeNewswire
Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform
November 02, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
September 25, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
August 30, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update
August 10, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference
August 01, 2023
From
Vor Biopharma
Via
GlobeNewswire
Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform
June 09, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in the Goldman Sachs Healthcare Conference
June 05, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update
May 11, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
April 18, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
March 23, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
February 21, 2023
From
Vor Biopharma
Via
GlobeNewswire
First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level
February 16, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings
January 19, 2023
From
Vor Biopharma
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.